SeaStar Medical Announces First Pediatric Patient Treated In A Commercial Setting With Its FDA-Approved QUELIMMUNE Therapeutic Device
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holding Corporation (NASDAQ:ICU) has treated its first pediatric patient in a commercial setting with its FDA-approved QUELIMMUNE™ therapeutic device for acute kidney injury (AKI). This milestone meets the FDA's deadline for patient treatments by August 20, 2024.
July 23, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical (NASDAQ:ICU) has successfully treated its first pediatric patient with its FDA-approved QUELIMMUNE™ device for acute kidney injury, meeting the FDA's treatment deadline.
The successful treatment of the first pediatric patient with the FDA-approved QUELIMMUNE™ device is a significant milestone for SeaStar Medical. It demonstrates the company's ability to meet regulatory deadlines and potentially opens up new revenue streams. This positive development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100